New hope for hard-to-treat breast cancer? drug duo targets PIK3CA mutation
NCT ID NCT07441512
First seen Mar 06, 2026 · Last updated May 02, 2026 · Updated 8 times
Summary
This study tests a combination of two drugs (inavolisib and eribulin) in people with advanced triple-negative breast cancer that has a specific genetic change called PIK3CA mutation. The goal is to see if the combo can shrink tumors. About 26 participants who have already tried at least one other treatment will take part. The study is not yet open for enrollment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.